嵌合抗原受体T细胞在结直肠癌中的应用:开创实体瘤免疫治疗新途径
本综述探讨嵌合抗原受体T(CAR-T)细胞疗法在结直肠癌(CRC)中的潜力,通过分析临床试验和突出CRC特异性靶点,讨论免疫抑制微环境、肿瘤异质性和物理屏障等限制CAR-T疗效的挑战,并介绍逻辑门控和双靶点CAR-T等新兴策略及与免疫检查点抑制剂联合应用以增强T细胞持久性和肿瘤浸润。
要点
- CAR-T细胞疗法在血液肿瘤中取得成功,为包括CRC在内的实体瘤治疗提供有前景的途径。
- CRC中CAR-T疗效受免疫抑制微环境、肿瘤异质性和物理屏障限制。
- 逻辑门控和双靶点CAR-T及与免疫检查点抑制剂联合是克服障碍的新兴策略。
核心结论
- 随着领域不断发展,CAR-T细胞疗法在革新CRC治疗格局方面具有显著潜力。
研究设计与样本
- 本综述通过分析临床试验并突出CRC特异性靶点,探讨CAR-T细胞疗法在CRC中的潜力。
主要发现
- CRC仍是全球主要健康负担,为最常见癌症之一且死亡率高。
- 尽管常规治疗取得进展,转移性CRC患者常面临选择有限和结局不佳。
- CAR-T细胞疗法在血液恶性肿瘤中 initially 成功,为包括CRC在内的实体瘤治疗提供有前景的途径。
- 免疫抑制微环境、肿瘤异质性和物理屏障限制CAR-T疗效。
- 逻辑门控和双靶点CAR-T细胞等新兴策略为克服这些障碍提供实用解决方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Colorectal cancer (CRC) remains a major global health burden, being one of the most prevalent cancers with high mortality rates. Despite advances in conventional treatment modalities, patients with metastatic CRC often face limited options and poor outcomes. Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC. This review explores the potential of CAR-T cell therapy in CRC by analyzing clinical trials and highlighting prominent CRC-specific targets. We discuss the challenges such as immunosuppressive microenvironment, tumor heterogeneity, and physical barriers that limit CAR-T efficacy. Emerging strategies, such as logic-gated and dual-targeting CAR-T cells, offer practical solutions to overcome these hurdles. Furthermore, we explore the combination of CAR-T cell therapy with immune checkpoint inhibitors to enhance T-cell persistence and tumor infiltration. As the field continues to evolve, CAR-T cell therapies hold significant potential for revolutionizing the treatment landscape of CRC.
引用
- Ouladan S, Orouji E. Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy. J Clin Oncol. 2025. PMID: 39805063. doi:10.1200/JCO-24-02081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。